Daily Archives: October 15, 2014

Frost & Sullivan Commends DianaPlantSciences for Developing Greener and Smarter Plant Cell Cultures

— DianaPlantSciences’ technology consists in the controlled culture of plant cells producing specific desired plant components, thus eliminating the need to grow the entire plant

PORTLAND, Ore., Oct. 16, 2014 /PRNewswire/ — Based on its recent analysis of the plant cell culture market, Frost & Sullivan recognizes DianaPlantSciences with the 2014 Global Frost & Sullivan Award for Visionary Innovation Leadership. DianaPlantSciences’ ceaseless efforts to integrate smart, sustainable technology into agricultural production methods have enabled it to address ever-evolving customer needs for smarter plant cell culture technologies. It has allowed clients to dispense with the conventional agricultural technology of field-grown plants, which is often inefficient, inapplicable to rare plant species and detrimental to the environment on a commercial scale.

In line with the Mega Trend of ‘Smart is the New Green’, DianaPlantSciences provides turnkey solutions to increase customers’ operational efficiency. This is achieved by encouraging the use of high-quality, full-traceability plant secondary metabolites as raw materials, whether contained in their original plant cells or extracted therefrom. Secondary metabolites obtained from plant cell culture technology are non-GMO, free from contaminants, and contain nutritional properties suited to pharmaceutical, nutraceutical and cosmeceutical applications.

DianaPlantSciences’ ability to design and commercialise the plant cell culture technology facilitates the culture of desired plant components in bioreactors, doing away with the need to grow an entire plant. In addition to enhancing operational efficiency and productivity, DianaPlantSciences’ meticulously designed manufacturing process drastically reduces the utilization of natural resources, such as agricultural land and manpower.

“Cultured in a controlled environment, plant cells are free from pests and contaminants such as heavy metals, pesticides and pollutants, resulting in high-quality yield,” said Frost & Sullivan Research Analyst Tharmathas Alagappan. “In addition, DianaPlantSciences’ minimal downstream processes, which dispense with the complex process of harvesting, transporting and extracting desired compounds from full grown plants, give a huge boost to energy efficiency.”

Overall, this disruptive technology is anticipated to raise the industry benchmark in quality, traceability as well as operational and energy efficiency.

Further showcasing its innovation abilities, DianaPlantSciences developed Cocovanol™, the first nutraceutical ingredient produced completely in a bioreactor via plant cell culture technology. Cocovanol Cocoa Actives contains significantly higher flavanol content than basic cocoa, and only traces of caffeine and theobromine. This makes Cocovanol™ a better source of nutrition, and raw material for the nutraceutical and cosmeceutical industry.

Importantly, DianaPlantSciences’ heavy R&D investments have allowed it to research rare plant species and thereby, to expand its intellectual portfolio. Its sophisticated plant cell culture technology permits it to explore and leverage an infinite number of plant species, as only a minute specimen sample is required to initiate micropropagation. This enables it to produce novel, proprietary ingredients that are patentable.

“The utilization of advanced bio-informatics to screen plant cell lines, synergized with its rare understanding of plant metabolic pathways, assists maximal product differentiation through the production of innovative plant phyto-actives,” noted Alagappan.

DianaPlantSciences harnesses its full intellectual capabilities to provide cutting-edge solutions, tailored to meet end-users demands. Frost & Sullivan firmly believes that the company’s plant cell culture solutions are visionary, and offer clients a competitive edge in the highly demanding industry.

Each year, Frost & Sullivan presents the Visionary Innovation Leadership award to companies that have demonstrated the understanding to leverage global Mega Trends, as well as to integrate the vision into processes to achieve strategic excellence. The award recognizes the efficacy of the recipient’s innovative process and the impact it has on business and society at large.

Frost & Sullivan’s Best Practices Awards recognizes companies in a variety of regional and global markets for outstanding achievement in areas such as leadership, technological innovation, customer service, and product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research.

About DianaPlantSciences

DianaPlantSciences is a company of DIANA – now part of SYMRISE -, a global company focused on organoleptic performance of natural ingredients for the food, pet food, nutraceutical, aquaculture and cosmetic industries. DIANA has revenues of over $500 million, employs over 1,500 people and is established in 22 countries.

Based in Portland, DianaPlantSciences spearheads the activities of DIANA in biosciences with a unique expertise in the sustainable production of natural ingredients from plant cell culture technology. For more information, visit DianaPlantSciences at www.dianaplantsciences.com.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:   Start the discussion
Join Us:      Join our community
Subscribe:    Newsletter on “the next big thing”
Register:     Gain access to visionary innovation

Contact:

Marc Philouze
DianaPlantSciences
Tel.: +1-503-505-6267
E-mail: mphilouze@dianaplantsciences.com

Adelaide Mendes
Best Practices Group
Frost & Sullivan
Tel.: +44-(0)-207-9157869
E-mail: adelaide.mendes@frost.com

Tianyin Pharmaceutical Provides Update on Filing of Form 10-K for Fiscal Year Ended June 30, 2014

CHENGDU, China, October 15, 2014 /PRNewswire/ — Tianyin Pharmaceutical Inc. (NYSE MKT: TPI, the “Company”), a pharmaceutical company that specializes in the development and sale of patented biopharmaceutical medicine, modernized tra…

Mindray Medical to Exhibit New Products at Upcoming Medical Equipment Fairs

SHENZHEN, China, October 15, 2014 /PRNewswire/ — Mindray Medical International Limited (“Mindray”, NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today that it will exhibit its late…

Finesse Introduces SmartVessel™, A Single-Use 3L vessel with Integrated Sensors for Cell Culture

SANTA CLARA, Calif., Oct. 15, 2014 /PRNewswire/ — Finesse Solutions, Inc, Santa Clara, CA, a manufacturer of measurement and control solutions for life sciences process applications, announced the launch of beta testing of SmartVessel™, a single-use 3 liter bioreactor vessel with integrated single-use sensors for cell culture applications of mammalian cells, stem cells, insect cells, and plant cells.

This stirred tank single-use bioreactor allows working volumes from 0.5L to 2.2L and is supplied as a completely preassembled and presterilized unit that is immediately ready to use. It eliminates the need for labor-intensive steps such as autoclaving or installation of probes, minimizing the time needed for process setup.

The SmartVessel leverages the same integrated SmartPuck sensor technology for pH, dissolved oxygen (DO) and temperature measurement as the SmartRocker. All wetted materials of the SmartVessel are USP class VI compliant. The SmartVessel also utilizes the same impeller configuration and agitator motor as the Finesse SmartGlass vessels and has been designed to provide almost identical performance in mixing, kLa, and thermal control, but with the efficiency and flexibility of single-use systems. It is both interchangeable with and comparable to in performance with the SmartGlass and readily interchangeable with the SmartRocker when used with the G3lab Universal Controller.

“SmartVessels represent the continued commitment of Finesse to bringing single-use solutions into the lab scale cell-culture market. Along with our SmartRocker and TruFluor pH/DO sensors, the SmartVessel will minimize end user labor in bioreactor cleaning and setup, and maintain fidelity of control. We anticipate that the SmartVessel will provide a unique, complete solution for process development and optimization, as well as production of seed cultures and cell banks,” stated Finesse Chief Technology Officer and co-founder, Dr. Mark Selker.

About Finesse Solutions, Inc.

California-based Finesse Solutions, Inc., has a proven record of providing turn-key, scalable solutions for single-use upstream bioprocessing. The Finesse product platform includes novel disposable sensors, modular automation hardware, and intelligent software that can harmonize data and technology transfer globally. Finesse also offers a complete set of services including commissioning and validation for rapid and reliable deployment of single-use equipment. For more information, please visit us at www.finesse.com.

ScinoPharm Recognized as API Supplier of the Year at Global Generics & Biosimilars Awards

TAINAN, October 15, 2014 /PRNewswire/ — ScinoPharm (TWSE:1789) announced that it was named the “Active Pharmaceutical Ingredient (API) Supplier of the Year” at the Global Generics and Biosimilars Awards co-hosted by Generics bulleti…

Complementary Medicine Use Linked to Healthcare Cost Savings, Finds Frost & Sullivan

– Targeted use of complementary medicines significantly reduces risk of disease-related events, hospitalisation costs and productivity losses

SYDNEY, Oct. 15, 2014 /PRNewswire/ — Escalating healthcare costs associated with the increasing burden of disease in Australia is a major challenge for government, private health insurers and individuals. Thus, there is growing pressure to find solutions to improve health outcomes and reduce healthcare expenditures. One available option is to motivate at-risk individuals to adopt a regimen that aims to reduce the risk of costly events associated with major chronic disease in terms of hospital separations and lost wage income due to illness. Use of complementary medicines among well-defined, high-risk populations can help decrease the occurrence of disease-attributed medical events and associated economic consequences.

Frost & Sullivan’s recent economic analysis, Targeted Use of Complementary Medicines: Potential Health Outcomes & Cost Savings in Australia, assesses the relationship between use of complementary medicines and potential healthcare cost savings and productivity gains. The research shows that notable net benefits can be realised through targeted use of certain scientifically substantiated complementary medicine regimens among high-risk individuals, such as calcium and vitamin D or magnesium for osteoporosis, omega-3, folic acid, B6 and B12, for cardiovascular disease (CVD), lutein and zeaxanthin for age-related eye disease, and St. John’s wort for moderate major depression.

For complimentary access to more information on this research, please contact Carrie Low Corporate Communications, at carrie.low@frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.

“A less-than-healthy society leads to an increase in medical service expenditure and a loss in labour productivity. This means less tax revenue for Commonwealth, State and Territory governments and increased healthcare costs; in other words, a less-than-healthy economy,” said Frost & Sullivan Global Program Director for the Chemicals, Materials and Food Practice, Christopher Shanahan.

For example, more than $1.6 billion in healthcare cost savings and wage income gains can be realized in 2015 if all women over the age of 50 with osteoporosis or osteopenia were to use calcium and vitamin D. Additionally, by targeting all Australians over the age of 55 with diagnosed CVD, the study found that after using an omega-3 regimen, a potential net benefit yield of nearly $490 million in net cost savings and productivity gains in 2015 is realisable. Also, a St. John’s wort intervention could save $256 million in wage income gains in 2015 if all adults aged 20 and over used this regimen at preventive intake levels.

“Determining the cost-effectiveness of using certain complementary medicines requires that many factors be considered such as which disease events are preventable, the efficacy of the complementary medicine under review, and consequently, the relative cost, before an informed decision can be made,” observed Shanahan. “However, once the link between the use of certain complementary medicines with scientifically-substantiated health potential and economic benefit is better understood, the decision to use the complementary medicine will be easier to make.”

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on “the next big thing”

Register:         Gain access to visionary innovation

Contact:
Carrie Low
Corporate Communications – Asia Pacific
P: +603-6204-5910
F: +603-6201-7402
E:  carrie.low@frost.com
http://www.frost.com

Logo – http://photos.prnasia.com/prnh/20141015/8521406003LOGO

“Steroids OUT!” A Korean Medicine Doctor Banning Chemical Medicine

-New Yorkers with Severe Lung Diseases, Here is Your Rescue!
SEOUL, South Korea, October 15, 2014 /PRNewswire/ — “About 123,000 patients with atopic dermatitis, rhinitis, and asthma and 32,000 …

Initial Pharmacokinetic Data From TRIBECA Study Support Potential For Bioequivalence Between Cynviloq And Albumin-Bound Paclitaxel

SAN DIEGO, Oct. 15, 2014 /PRNewswire/ — Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, announced today positive results from recently analyzed pharmacokinetic (PK) data from the first eight (8) patients enrolled in its ongoing TRIBECA™ (TRIal establishing BE between Cynviloq™ and Albumin-bound paclitaxel) registrational trial. The data from these patients supports earlier completion of the study with the aim of seeking to establish bioequivalence (BE) to albumin-bound paclitaxel to obtain Food and Drug Administration (FDA) marketing approval for Cynviloq (paclitaxel polymeric micelle for injection).

Sorrento amended the current BE cross-over design protocol of the TRIBECA study to un-blind the first 8 patients to reassess the sample size of 100 patients estimated from simulation of historical PK data. Based on the cross-over data and the analyses of relevant paclitaxel plasma PK data performed by two independent PK consulting groups, the success of the BE approach for seeking approval of Cynviloq remains subject to FDA review and discussion. Sorrento does not plan to un-blind additional patient data. Current sample size point estimates suggest that the enrollment target for the current study can be reduced to nearly half of the original target.

“We are pleased that the favorable PK data from actual patients treated have thus far exceeded our expectations,” said Henry Ji, Ph.D., President and Chief Executive Officer of Sorrento. “Guided by these promising data, Sorrento plans to reduce the TRIBECA patient sample size to accelerate filing for FDA approval.”

About Sorrento Therapeutics, Inc.

Sorrento is an oncology company developing new treatments for cancer and associated pain. Sorrento’s most advanced asset Cynviloq™, the next-generation paclitaxel, commenced its registrational trial in March 2014 and is being developed under the abbreviated 505(b)(2) regulatory pathway. Sorrento is also developing RTX, a non-opiate TRPV1 agonist currently in a Phase 1/2 study at the NIH to treat terminal cancer patients suffering from intractable pain. The Company has made significant advances in developing human monoclonal antibodies, complemented by a comprehensive and fully integrated antibody drug conjugate (ADC) platform that includes proprietary conjugation chemistries, linkers, and toxic payloads. Sorrento’s strategy is to enable a multi-pronged approach to combating cancer with small molecules, mono- and bi-specific therapeutic antibodies, and ADCs.

Forward-Looking Statements

This press release contains forward-looking statements under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements on Cynviloq include: (i) results from recently analyzed PK data from the first eight (8) patients enrolled in the ongoing TRIBECA™ registrational trial suggest that Cynviloq is likely to be representative of the full patient data in the TRIBECA study; (ii) the reduction of the enrollment target for the current study will support the bioequivalence strategy for Cynviloq; (iii) whether the FDA will view the data and results of the TRIBECA study as sufficient to support approval based on bioequivalence and (iv) the expectation that the NDA submission can be accelerated successfully based on a smaller enrollment total, if at all; (v) the risks of this strategy as well as the advances made in developing human monoclonal antibodies, if any; and (vi) other matters described in Sorrento’s Annual Report on Form 10-K for the year ended December 31, 2013, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.